BiomX Inc.
BiomX Inc.
Your view on PHGE-UN
Overview
What the company does, where it operates, and who runs it.
About BiomX Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jonathan Eitan Solomon MBA
- Headquarters
- 22 Einstein Street, Ness Ziona, IL
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jonathan Eitan Solomon MBA
- Headquarters
- 22 Einstein Street, Ness Ziona, IL
Headquartered in Ness Ziona, Israel, BiomX Inc. is a clinical-stage biotechnology company established in 2015, dedicated to advancing microbiome-based therapies. The firm harnesses both naturally occurring and genetically engineered bacteriophage technologies to precisely identify and eliminate detrimental bacterial strains. BiomX's therapeutic efforts span conditions impacting skin appearance, as well as a spectrum of chronic diseases, including inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). The company's robust development pipeline includes several promising candidates. BX004, a phage-based treatment for cystic fibrosis patients suffering from persistent Pseudomonas aeruginosa respiratory infections, is presently undergoing Phase 1b/2a clinical evaluation. Another key asset, BX005, is a topical phage cocktail currently in Phase 1/2 clinical studies, engineered to combat Staphylococcus aureus (S. aureus), a bacterium linked to various disease manifestations. Additionally, BX003, an orally administered phage cocktail, is progressing through Phase 1b/2a trials, targeting a specific gut bacterium found in individuals with IBD and PSC. Beyond these, BiomX is engaged in a colorectal cancer initiative that utilizes engineered phages with diverse therapeutic payloads, delivered intravenously to neutralize Fusobacterium nucleatum bacteria residing within the tumor's microenvironment.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for BiomX Inc., and the rating behind it. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for BiomX Inc.. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for BiomX Inc.. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for BiomX Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for BiomX Inc.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
BiomX Inc. valued side by side against its closest peers. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold BiomX Inc., and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by BiomX Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming BiomX Inc.. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming BiomX Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for BiomX Inc.. Press releases and market coverage, newest first.